Opaleye Management’s Accelerate Diagnostics AXDX Stock Holding History

Opaleye Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,500	Closed	-$1.61M	–	54
2015 Q4	$1.61M	Sell	7,500 -2,000	-21%	-$365K	0.67%	45
2015 Q3	$1.54M	Sell	9,500 -560	-6%	-$121K	0.76%	39
2015 Q2	$2.6M	Hold	10,060	–	–	1.03%	32
2015 Q1	$2.26M	Buy	10,060 +60	+0.6%	+$12.5K	1.05%	29
2014 Q4	$1.92M	Buy	10,000 +1,080	+12%	+$231K	0.97%	30
2014 Q3	$1.92M	Buy	+8,920	New	+$1.73M	1.49%	22

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

MGM

Miura Global Management New York $43.8M AUM 53.8% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Opaleye Management's AXDX Position: Q1 2016 in Review

Opaleye Management sold out of Accelerate Diagnostics (AXDX) in Q1 2016, closing a stake of 7,500 shares — an estimated $1.61M sold.

Opaleye Management first reported a position in AXDX in Q3 2014 and held it in 6 quarters. The position peaked at $2.6M in Q2 2015. 92 funds tracked by Wall St. Rank hold AXDX as of Q1 2016.

Opaleye Management reported no remaining Accelerate Diagnostics position as of Q1 2016 after selling out during the quarter.
Opaleye Management sold 7,500 Accelerate Diagnostics shares in Q1 2016, an estimated $1.61M.
Opaleye Management first reported a position in Accelerate Diagnostics in Q3 2014 and held it in 6 quarters.
Opaleye Management's Accelerate Diagnostics position peaked at $2.6M in Q2 2015.
92 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2016.

Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.